Abstract: The invention relates to a method for determining a condensation product of a Pictet-Spengler reaction between a carbonyl compound, in particular an aldehyde, preferably formaldehyde, and an amine in a body fluid removed from a human and/or in cells taken from a human, wherein a chemical, physical, or physico-chemical determination of the condensation product as an analyte is carried out on the body fluid and/or the cells. The invention also relates to novel analytes useful therefor.

Abstract: The invention relates to phenoxy derivatives with glycosidically bound sugar moieties, pharmaceutical compositions containing such compounds, uses of such compounds and compositions, and methods of making such compounds and pharmaceutical compositions.

Abstract: The invention relates to a method for preparing a dietetic or pharmaceutical composition, comprising the following steps: a) a preparation containing rutin, in particular ground tatary buckwheat, is mixed with a protein solution in a weight ratio protein solution/buckwheat from 1 to 100 (or vice versa), wherein before the addition of buckwheat, the protein solution has been heated above room temperature, b) the mixture from step a) is held for a period of at least 10 to 1,000 s at a temperature >50° C., and c) subsequently to step b), the mixture is cooled down to a temperature below 45° C. The invention further relates to thus obtainable preparations and to the uses thereof.

Abstract: The invention relates to phenoxy derivatives with glycosidically bound sugar moieties, pharmaceutical compositions containing such compounds, uses of such compounds and compositions, and methods of making such compounds and pharmaceutical compositions.

Abstract: The invention relates to a method of solubilizing a pharmaceutical active ingredient, to the use of this method of making a pharmaceutical composition in the form of a dermal and/or transdermal preparation, to a pharmaceutical composition containing this compound, and to at least one pharmaceutical active ingredient, an aerosol dispenser with such a composition, and to a method of making such a composition.

Abstract: The invention relates to a method for preparing a dietetic or pharmaceutical composition, comprising the following steps: a) a preparation containing rutin, in particular ground tatary buckwheat, is mixed with a protein solution in a weight ratio protein solution/buckwheat from 1 to 100 (or vice versa), wherein before the addition of buckwheat, the protein solution has been heated above room temperature, b) the mixture from step a) is held for a period of at least 10 to 1,000 s at a temperature >50° C., and c) subsequently to step b), the mixture is cooled down to a temperature below 45° C. The invention further relates to thus obtainable preparations and to the uses thereof.

Abstract: 5- or 6-substituted .beta.-carboline-3-carboxylic acid esters of Formula I ##STR1## wherein R.sup.1 is hydrogen, nitrilo, halogen, lower alkyl or lower alkoxy, andR.sup.3 is a branched C.sub.3-6 alkyl group which is optionally substituted by halogen, or a C.sub.3-6 cycloalkyl group which is optionally methyl-substituted, are valuable pharmaceuticals.

Abstract: 5- or 6-substituted .beta.-carboline-3-carboxylic acid esters of Formula I ##STR1## wherein R.sup.1 is hydrogen, nitrilo, halogen, lower alkyl or lower alkoxy, andR.sup.3 is a branched C.sub.3-6 alkyl group which is optionally substituted by halogen, or a C.sub.3-6 cycloalkyl group which is optionally methyl-substituted, are valuable pharmaceuticals.

Abstract: (2-Haloergolinyl)-N',N'-diethylurea derivatives of Formula I ##STR1## and the salts thereof, wherein R is hydrogen, alkyl of up to 6 carbon atoms, or alkenyl of up to 3 carbon atoms,X is halogen, ##STR2## is a CC single or CC double bond, and the urea residue in the 8-position can be in the .alpha.- or .beta.-configuration, have neuropsychotropic properties.As a result, they are excellently suitable for treatment of psychotic disturbances and emesis.

Abstract: Substituted ergolines of the formula ##STR1## and their acid addition salts, wherein the urea side chain in the 8-position can be in the d.alpha.- or .beta.-configuration, C.sub.2 C.sub.3 and C.sub.9 C.sub.10 are a CC single or C.dbd.C double bond, andR is hydrogen or NR'R" wherein R'R" is O.sub.2, H.sub.2, C.sub.1-4 -dialkyl, or, together, they form a 3- to 9-membered ring, or R' and R" individually are hydrogen, C.sub.1-4 -alkyl, or C.sub.1-10- -acyl,R.sup.1 is hydrogen, C.sub.1-4 -alkyl, C.sub.1-10 -acyl, C.sub.6-8 -aryl, or C.sub.1-4 -alkylsulfonyl,R.sup.2 is hydrogen or halogen if C.sub.2 C.sub.3 is a C.dbd.C double bond, or hydrogen if C.sub.2 C.sub.3 is a CC single bond,R.sup.6 is C.sub.1-4 -alkyl,show a pronounced effect on the central nervous system and are suitable, for example, as antidepressants, neuroleptics, or antihypertensives.

Abstract: Terguride and its physiologically compatible salts can be used for the treatment of geriatric deficiencies, e.g., in doses of 0.1-5.0 mg/day.

Abstract: 3-Substituted beta-carbolines of the formula ##STR1## wherein R.sup.A is H, F, Cl, Br, I, NO.sub.2, CN, CH.sub.3, CF.sub.3, SCH.sub.3, NR.sup.16 R.sup.17 or NHCOR.sup.16,wherein R.sup.16 and R.sup.17 are the same or different and each is hydrogen or alkyl, alkenyl or alkynyl each of up to 6 C-atoms, aralkyl or cycloalkyl each of up to 10 C-atoms,or wherein R.sup.16 and R.sup.17 together form a saturated or unsaturated 3-7 membered heterocyclic ring;said compounds possess valuable psychotropic properties which make them useful for example as tranquilizers.

Abstract: Terguride and its physiologically compatible salts have been discovered to be useful in the treatment of essential hypertonia, e.g., in humans, e.g., in doses of 0.1-1.0 mg/day.

Abstract: Substituted 5H-pyrimido[5,4-b]indoles of Formula I ##STR1## wherein R.sup.2 is halogen; the oxadiazolyl group ##STR2## wherein R" is lower alkyl with up to 3 carbon atoms; C.sub.1-5 -alkyl, cycloalkyl, aralkyl, or aryl; OR.sup.I, SO.sub.n R.sup.I with n being 0, 1, or 2, or ##STR3## wherein R.sup.I is hydrogen, C.sub.1-5 -alkyl, cycloalkyl, aralkyl, or aryl; ##STR4## wherein R.sup.II and R.sup.III are hydrogen, C.sub.1-5 -alkyl, C.sub.3-5 -alkenyl, cycloalkyl, aralkyl, aryl, or, with the connecting N-atom, a 5- or 6-membered heterocyclic ring; andR.sup.A is hydrogen; the oxadiazolyl group ##STR5## wherein R" is lower alkyl with up to 3 carbon atoms; halogen, nitro, OR.sup.I, SO.sub.n R.sup.I with n being 0, 1, or 2, ##STR6## wherein R.sup.I is hydrogen, C.sub.1-5 -alkyl, cycloalkyl, aralkyl, or aryl; ##STR7## wherein R.sup.II and R.sup.III are hydrogen, C.sub.1-5 -alkyl, cycloalkyl, C.sub.3-5 -alkenyl, aralkyl, aryl, or, with the connecting N-atom, a 5- or 6-membered heterocyclic ring; orPO(OR).sub.

Abstract: The treatment of psychosis with N-(D-6-methyl-8-isoergolin)-N'N-diethylurea.

Abstract: 3-substituted beta-carbolines of the formula ##STR1## wherein R.sup.C is hydrogen, lower alkyl, alkoxyalkyl of up to 6 C-atoms, cycloalkyl of 3-6 C-atoms, aralkyl of up to 8 C-atoms, or (CH.sub.2).sub.n OR.sup.20wherein R.sup.20 is alkyl of up to 6 C-atoms, cycloalkyl of 3-6 C-atoms or aralkyl of up to 8 C-atoms and n is an integer of 1 to 3;Y is oxygen, two hydrogen atoms or NOR.sup.1,wherein R.sup.1 is hydrogen, lower alkyl, aryl or aralkyl of up to 6 C-atoms, COR.sup.2, wherein R.sup.2 is lower alkyl of up to 6 C-atoms,or Y is CHCOOR.sup.3, wherein R.sup.3 is hydrogen or lower alkylor Y is NNR.sup.4 R.sup.5,wherein R.sup.4 and R.sup.5 can be the same or different and each is hydrogen, lower alkyl, C.sub.6-10 -aryl, C.sub.7-10 -aralkyl or CONR.sup.6 R.sup.7,wherein R.sup.6 and R.sup.7 can be the same or different and each is hydrogen or lower alkyl or R.sup.4 and R.sup.

Abstract: Compounds of the formula ##STR1## or a pharmaceutically acceptable salt thereof, wherein R.sub.1 is alkyl of 2-6 carbon atoms, ##STR2## n is 1, or 2, m is 0 or 1,R.sub.2 is alkyl of 1-6 carbon atoms, ##STR3## is a CC single bond or a CC double bond, and the 8-positioned urea residue can be in the .alpha.- or .beta.-position, have valuable pharmacological properties, e.g., lactation inhibition and anti-Parkinsonism.

Abstract: 4-(Polyalkoxyphenyl)-2-pyrrolidones of the formula ##STR1## wherein R.sub.1 and R.sub.2 each are hydrocarbon of up to 18 carbon atoms at least one being other than methyl, a heterocyclic ring, or alkyl of 1-5 carbon atoms substituted by halogen, OH, COOH, alkoxy, alkoxycarbonyl or an amino group; R' is H, alkyl, aryl or acyl; and X is O or S; possess neuropsychotropic activity. The compounds wherein X is O can be produced by saponifying and decarboxylating a corresponding 2-pyrrolidone-3-carboxylic acid alkyl ester or cyclizing a corresponding 3-phenyl-4-amino-butyric acid or alkyl ester thereof. The pyrrolidones can be converted to the corresponding thiopyrrolidones by reaction with phosphorous pentasulfide in the presence of base.

Abstract: Novel 5-(substituted phenyl)-oxazolidinones and their sulfur analogs of Formula I ##STR1## wherein R.sub.1 is optionally substituted lower alkyl, cycloalkyl or cycloalkylalkyl;R.sub.2 is hydrogen, optionally substituted lower alkyl, cycloalkyl, cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, alkenyl or a heterocyclic group;R.sub.3 is hydrogen, optionally substituted lower alkyl, alkenyl, alkynyl, optionally substituted aryl, optionally substituted aralkyl, or optionally substituted acyl;R.sub.4 is hydrogen or optionally substituted lower alkyl;R.sub.5 is hydrogen or optionally substituted lower alkyl or optionally substituted lower alkoxycarbonyl; andX is oxygen or sulfur, have valuable pharmacological effects.

Abstract: 4-(Polyalkoxyphenyl)-2-pyrrolidones of the formula ##STR1## wherein R.sub.1 and R.sub.2 are hydrocarbon; R.sub.3 is hydrogen or methoxy;R is O-alkyl, O-aryl, O-aralkyl, NH.sub.2, NH-alkyl, NH-aryl, NH-aralkyl, N(alkyl).sub.2, N(aryl).sub.2 or ##STR2## AND X is O or S, are neuropsychotropic agents.